Menu
Menu
Granules India has achieved a significant milestone with USFDA approval for its generic Lisdexamfetamine Dimesylate chewable tablets, providing a more affordable option for treating ADHD and binge eating disorder. This approval addresses critical drug shortages in the U.S. and strengthens Granules’ presence in the global pharmaceutical market.
Introduction: Zydus Lifesciences Ltd has accomplished a significant milestone with the final approval from the United States Food and Drug Administration (USFDA) for its typical model of Paliperidone prolonged-release capsules, […]